Complement Inactivating Agents
"Complement Inactivating Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that negatively regulate the cascade process of COMPLEMENT ACTIVATION. Uncontrolled complement activation and resulting cell lysis is potentially dangerous for the host.
| Descriptor ID |
D051056
|
| MeSH Number(s) |
D27.505.696.477.656.500
|
| Concept/Terms |
Complement Inactivating Agents- Complement Inactivating Agents
- Agents, Complement Inactivating
- Inactivating Agents, Complement
- Complement Inhibitors
- Inhibitors, Complement
- Complement Inhibiting Agents
- Agents, Complement Inhibiting
- Inhibiting Agents, Complement
|
Below are MeSH descriptors whose meaning is more general than "Complement Inactivating Agents".
Below are MeSH descriptors whose meaning is more specific than "Complement Inactivating Agents".
This graph shows the total number of publications written about "Complement Inactivating Agents" by people in this website by year, and whether "Complement Inactivating Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 1 | 0 | 1 |
| 2015 | 0 | 1 | 1 |
| 2019 | 1 | 1 | 2 |
| 2020 | 0 | 1 | 1 |
| 2021 | 1 | 0 | 1 |
| 2023 | 1 | 0 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Complement Inactivating Agents" by people in Profiles.
-
The role of complement in kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2024 Sep; 106(3):369-391.
-
The effect of complement C3 or C5 inhibition on geographic atrophy secondary to age-related macular degeneration: A living systematic review and meta-analysis. Surv Ophthalmol. 2024 May-Jun; 69(3):349-361.
-
A prospective phase 2 clinical trial of a C5a complement inhibitor for acute GVHD with lower GI tract involvement. Bone Marrow Transplant. 2023 09; 58(9):991-999.
-
Characterizing New-Onset Exudation in the Randomized Phase 2 FILLY Trial of Complement Inhibitor Pegcetacoplan for Geographic Atrophy. Ophthalmology. 2021 09; 128(9):1325-1336.
-
Complement inhibitor Crry expression in mouse placenta is essential for maintaining normal blood pressure and fetal growth. PLoS One. 2020; 15(8):e0236968.
-
Use of the terminal complement inhibitor eculizumab in paediatric heart transplant recipients. Cardiol Young. 2020 Jan; 30(1):107-113.
-
Approaching treatment of transplant-associated thrombotic Microangiopathy from two directions with Eculizumab and transitioning from Tacrolimus to Sirolimus. Transfusion. 2019 11; 59(11):3519-3524.
-
Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial. Ophthalmology. 2020 02; 127(2):186-195.
-
Upcoming Therapies for Age-related Macular Degeneration. Int Ophthalmol Clin. 2019; 59(1):155-171.
-
Thrombocytopenia-Associated Multiple Organ Failure and Acute Kidney Injury. Crit Care Clin. 2015 Oct; 31(4):661-74.